At 4.2% CAGR, Europe Infectious Disease Therapeutics Market is Projected to be worth US$ 49,108.21 million by 2030, says Business Market Insights

According to Business Market Insights' research, the Europe infectious disease therapeutics market was valued at US$ 35,451.86 million in 2022 and is projected to reach US$ 49,108.21 million by 2030, registering a CAGR of 4.2% from 2022 to 2030. Rising prevalence of infectious disease and escalating threat of antibiotic resistance are among the critical factors attributed to drive the Europe infectious disease therapeutics market growth.

Antibiotic resistance serves as a compelling driver of growth in the infectious disease therapeutics market. With the escalating threat posed by drug-resistant pathogens, there is an urgent need for the development of novel antimicrobial therapies to combat resistant infections. As traditional antibiotics become less effective against resistant strains, pharmaceutical companies are investing in R&D to discover innovative therapeutic solutions. The demand for new treatments is further fueled by the alarming rise in antibiotic-resistant infections worldwide, which result in prolonged illness, increased healthcare costs, and higher mortality rates. This growing market is characterized by a focus on novel drug targets, such as bacterial virulence factors and host-pathogen interactions, as well as the exploration of alternative treatment modalities, including phage therapy and immunotherapy. As the challenge of antibiotic resistance intensifies, the infectious disease diagnostics market continues to expand, driven by the imperative to address this critical public health concern.

On the contrary, emergence of anti-infective drugs resistance and associated side effects hamper the growth of the Europe infectious disease therapeutics market.

Based on drug class, the Europe infectious disease therapeutics market is segmented into anti-viral, anti-bacterial, anti-fungal, and others. The anti-viral segment held 44.3% market share in 2022, amassing US$ 15,704.87 million. It is projected to garner US$ 21,958.32 million by 2030 to register 4.3% CAGR during 2022-2030.

In terms of indication, the Europe infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV segment held 35.6% share of Europe infectious disease therapeutics market in 2022, amassing US$ 12,621.45 million. It is anticipated to garner US$ 18,226.31 million by 2030 to expand at 4.7% CAGR during 2022-2030.

Based on route of administration, the Europe infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held 55.5% market share in 2022, amassing US$ 19,661.59 million. It is projected to garner US$ 27,790.68 million by 2030 to register 4.4% CAGR during 2022-2030.

In terms of distribution channel, the Europe infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held 49.2% share of Europe infectious disease therapeutics market in 2022, amassing US$ 17,459.29 million. It is anticipated to garner US$ 24,749.49 million by 2030 to expand at 4.5% CAGR during 2022-2030.

Based on country, the Europe infectious disease therapeutics market is categorized into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 26.5% share of Europe infectious disease therapeutics market in 2022. It was assessed at US$ 9,397.66 million in 2022 and is likely to hit US$ 13,191.02 million by 2030, registering a CAGR of 4.3% during 2022-2030.

Key players operating in the Europe infectious disease therapeutics market are AbbVie Inc, Astellas Pharma Inc, Bayer AG, BioCryst Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc, Merck & Co Inc, Pfizer Inc, and Shionogi & Co Ltd, among others.

• In April 2022, Pfizer Inc. declared its intention to purchase ReViral Ltd. The goal of ReViral Ltd., a clinical-stage biopharmaceutical business, is to find, create, and market innovative antiviral medications that specifically target the respiratory syncytial virus (RSV). Pfizer Inc. will purchase ReViral for up to US$ 525 million under the terms of the agreement, which includes upfront costs and development milestones.
  
  

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com